FSD Pharma Stock (NASDAQ:HUGE), Trade Ideas

FSD Pharma

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Psyched New - option 1

Biotech

Cannabis

Psychedelics

AWKNF

BETRF

CMND

FLHLF

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

MDXXF

MNMD

OPTHF

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans&#39; Trips And More

News

CMPS

CYBN

SILO

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

Financing

Legal

Management

Global

ATAI

ENVB

NUMIF

Psychedelics Headlines: Substitution Survey, Frank Herbert&#39;s Magic Mushrooms, Celestial Plans And News Review

FSD Pharma Inc. - Class B Subordinate Voting Shares

FSD Pharma Inc

Huge Amount Group Ltd

Beginning investors often ask, "What makes certain stocks go up, while others don't appreciate at all?" Although there are several answers, one of the main reasons that stocks move higher is when good earnings reports are released.
Investors want to own stocks that have increased earnings over the past year and beaten the analyst consensus estimates. Analysts' opinions often influence stock movements, so when a company beats the analysts' estimates it sends a message to investors that its stock is undervalued. Consequently, the stock often moves up substantially following an earnings beat.
Take a look at two real estate investment trusts (REITs) that just beat the estimates on first-quarter earnings, revenue and forward guidance.
Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) is a Bethesda, Maryland-based hotel REIT that invests in upscale hotel and resort properties in or near 13 urban markets in major U.S. gateway cities. Most of its 46 properties are located in California and Florida.&nbsp;
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
</ul>
Pebblebrook Hotel has been on a tear since November when it traded in the mid $11 range. Its total return before its first-quarter earnings report was 31.77%. Much of that was because of a strong fourth-quarter 2023 earnings report in February that easily beat the Street estimates and its year-over-year results for funds from operations (FFO) and revenue.
It wasn't surprising that on April 24, it repeated that performance with first-quarter operating results. Adjusted funds from operations (AFFO) of $0.21 per share beat the consensus estimate of $0.15 per share by 40% and walloped its FFO of $0.11 from the first quarter of 2023. Revenue of $314.069 million was ahead of the consensus estimate of $303.776 million and also topped its revenue of $305.719 million from the first quarter of 2023.
In addition, Pebblebrook announced it expects AFFO of $0.59-$0.63 per share for the second quarter of 2024. Analysts were expecting $0.56 per share.&nbsp;
Pebblebrook was up about 1% in early morning trading after the earnings release.
Trending
<ul>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
Agree Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is a Bloomfield Hills, Michigan-based triple-net-lease REIT, with a focus on retail properties. Its portfolio includes 2,161 owned and operated properties totaling 45 million square feet across 49 states. Sixty-nine percent of its tenants are investment grade, including well-known names like Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) and Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>).
Despite an excellent long-term track record since its initial public offering in 1994, Agree Realty has been an underperformer in 2024. Before the earnings release, it had a total return of negative 8.2% year to date. Over the past 52 weeks, the total return was negative 9.27%.&nbsp;
But that hasn't tempered management's optimism and enthusiasm. Agree Realty has seen substantial insider buying over the past 12 months as share prices have declined. This chart shows the large number of shares bought by insiders over the past three and 12 months, as opposed to shares sold:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Insider Trade</td>
<td>3 Months</td>
<td>12 Months</td>
</tr>
<tr>
<td>Number of shares bought</td>
<td>177,547</td>
<td>383,335</td>
</tr>
<tr>
<td>Number of shares sold</td>
<td>31,825</td>
<td>48,189</td>
</tr>
<tr>
<td>Total shares traded</td>
<td>209,372</td>
<td>431,524</td>
</tr>
<tr>
<td>Net activity</td>
<td>145,722</td>
<td>335,146</td>
</tr>
</tbody>
</table>
</figure>
Additionally, on April 8, Agree Realty announced an increase in its monthly common dividend from $0.247 to $0.25, giving it a 2.9% annual raise. The dividend will be paid on May 14 to shareholders of record as of the close of business on April 30, with the ex-dividend date on April 29. A dividend raise just before an earnings announcement is often a positive sign that upcoming earnings will meet or exceed expectations.&nbsp;
So perhaps it's not too surprising that on April 24, Agree Realty announced its first-quarter earnings and the results were excellent. FFO of $1.03 per share beat the analysts' estimate of $1.01 per share. The FFO also topped Agree's first-quarter 2023 FFO of $0.98 per share. Revenue of $149.453 million beat the consensus estimate of $146.462 million and was an 18.03% increase from revenue of $126.618 million in the first quarter of 2023.&nbsp;
On full year 2024 AFFO, Agree said it sees $4.10-$4.13 per share. The Street's estimate was $4.07. Investors were impressed, and shares traded over 2% higher in early morning trading following the report&#8217;s release.
Read Next:
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>

REIT

Real Estate

Two REITs That Just Crushed Earnings Estimates And Guidance

Employees at Cresco Labs Inc.'s (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#CSE">CL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) (FSE: 6CQ), the Massachusetts-based cannabis cultivation operations voted overwhelmingly to approve their first union contract with the United Food and Commercial Workers (UFCW) Local 328 more than three years ago. Now, the growers, supervisors and other agricultural workers at Cresco's operations opted to reverse the process.
With their contract nearing the June expiration date, the workers decided to de-unionize, instead of negotiating another organized labor deal, according to <a href="https://mjbizdaily.com/cresco-labs-cannabis-cultivation-workers-in-massachusetts-exit-union/">documents obtained</a> by MJBizDaily.
Wyatt Brissette, an employee at the Chicago-based multi-state cannabis operator who is behind the movement, said the scheduled wage increases were not in accordance with inflation, while promised benefits were "arguably worse" than for nonunion workers.
"We felt as if (the union) didn't match what we needed," Brissette, who was supported by a majority of his co-workers said.&nbsp;"We were pretty much paying them for nothing."
He also noted that "an overwhelming number of people" were ready to "put it back into Cresco's hands."
Lindsey Dadourian, senior vice president of employee and labor relations at Cresco, praised the move.
"We are very proud that our employees in Fall River have signaled their trust in Cresco by choosing to work directly with us," Dadourian told MJBizDaily."We will continue to support our employees while also working to maintain positive and productive relationships with the local unions that continue to represent some of our employees elsewhere."
<h3 class="wp-block-heading">Curaleaf Amidst Arizona Workers&#8217; Rally</h3>
Meanwhile, employees at Curaleaf Holdings, Inc.'s (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CURA#CSE">CURA</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) store in Phoenix, Arizona joined a 4/20 protest on Saturday, organized by United Food and Commercial Workers International Union Local 99 at a company store on East Camelback Road near North Seventh Street. The protesters asked for safer working conditions, full-time employment and a living wage, <a href="https://www.azcentral.com/story/news/local/phoenix/2024/04/21/cannabis-workers-picket-phoenix-dispensary-after-negotiations-stall/73399366007/">reported</a> Arizona Central.
According to a recent National Labor Relations Board ruling, Curaleaf "refused and neglected" to acknowledge the union and work on a contract. The New York-based multi-state cannabis operators have appealed the ruling in the federal court.
In a letter to the company&#8217;s labor relations manager, Ryan Gonsalves, protesters warned of alleged misinformation related to the bargaining process and increase in salaries.
&#8220;The Union only asks that Curaleaf give notice of the raises and an opportunity for the Union to quickly review the proposal for any issues, such as fairness," the letter stipulates. "Of course, the Union and Curaleaf may agree to future raises through bargaining, but Curaleaf employees have gone long enough without a pay increase."
See also: <a href="https://www.benzinga.com/markets/cannabis/21/06/21666416/cannabis-unionization-efforts-continue-to-grow-across-several-states-ma-and-cal-the-latest">Cannabis Unionization Efforts Continue To Grow Across Several States, MA And Cal The Latest</a>

Politics

CRLBF

CSE:CL

CSE:CURA

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Cannabis (De)Unionization: Here's What's New On The Frontlines Of Labor Organizing Among Weed Workers

RDDT

Reddit Says Improving The User Experience For Redditors By Introducing Direct Shortcut To Conversations While Keeping The Post Context Accessible

Phunware, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) shares are trading higher on Wednesday after the company disclosed the renewal or extension of several<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38401286/phunware-signs-multi-year-renewals-of-mobile-solutions-with-major-hospitality-and-healthcare-custo" rel="noreferrer noopener">&nbsp;healthcare and hospitality customer contracts</a>.&nbsp;
These renewals underscore the value customers&nbsp;are receiving&nbsp;from Phunware&#8217;s mobile solutions to enhance the visitor experience for hospital patients and hotel guests.
The Phunware-powered hospitality app generates&nbsp;six figures&nbsp;plus annual ancillary guest revenue for a typical customer, the company said in a press release.
&#8220;Hospitality and healthcare providers need technology that grows with them as they integrate the full visitor journey into a mobile platform,&#8221; said Mike Snavely, CEO of Phunware.&nbsp;
For hospitality, Phunware&#8217;s technology streamlines the guest experience from booking dining reservations to resort experiences directly through the app.&nbsp;
&#8220;These renewals show the significance of our exceptional mobile experiences and how they generate an investable ROI for our customers,&#8221; Snavely added.
Phunware has ties to&nbsp;Donald Trump&nbsp;dating back to 2020 when the company announced that it was working on&nbsp;the development, launch&nbsp;and&nbsp;ongoing management of the Trump-Pence&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/03/37620241/whats-going-on-with-trump-linked-phunware-stock-tuesday" rel="noreferrer noopener">2020 Reelection Campaign&#8217;s mobile application portfolio.</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>,&nbsp;PHUN stock has lost over 79% in the past year.&nbsp;
Price Action:&nbsp;PHUN shares are trading higher by 1.95% to $6.28 at last check Wednesday.

Equities

Markets

Movers

General

PHUN

Why Trump-Linked Phunware Shares Are Rising Today

Raymond James analyst Brad Sturges maintains DREAM INDL REAL ESTATE INVT TR (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DIR#TSX">DIR</a>) with a Outperform and lowers the price target from C$16.5 to C$16.

Price Target

Analyst Ratings

TSX:DIR

Raymond James Maintains Outperform on DREAM INDL REAL ESTATE INVT TR, Lowers Price Target to C$16

TD Cowen analyst Marc Bianchi maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and raises the price target from $47 to $48.

TD Cowen Maintains Buy on Halliburton, Raises Price Target to $48

Raymond James analyst Brad Sturges maintains CANADIAN APARTMENT PROPERTIES REAL (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAR#TSX">CAR</a>) with a Outperform and lowers the price target from C$60 to C$56.5.

TSX:CAR

Raymond James Maintains Outperform on CANADIAN APARTMENT PROPERTIES REAL, Lowers Price Target to C$56.5

Reddit Says Rolling Out Updates To Our iOS And Android Apps To Make It Easier And Faster To Get To Conversations

RBC Capital analyst Nik Modi maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Sector Perform and raises the price target from $123 to $126.

RBC Capital Maintains Sector Perform on Kimberly-Clark, Raises Price Target to $126

MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1949.0, with a high estimate of $2150.00 and a low estimate of $1800.00. Surpassing the previous average price target of $1930.00, the current average has increased by 0.98%.
<img src="https://www.benzinga.com/files/images/story/2024/1713978084_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive MercadoLibre. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1800.00</td>
<td>$2000.00</td>
</tr>
<tr>
<td>Kaio Prato</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1800.00</td>
<td>$1900.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1800.00</td>
<td>$2000.00</td>
</tr>
<tr>
<td>Tobias Stingelin</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$1940.00</td>
<td>$1990.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$2000.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$2000.00</td>
<td>-</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$2150.00</td>
<td>$2000.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$2000.00</td>
<td>$1900.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$2000.00</td>
<td>$1850.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2000.00</td>
<td>$1800.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MercadoLibre. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MercadoLibre compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of MercadoLibre's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MELI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MercadoLibre analyst ratings.</a>
<h2>Discovering MercadoLibre: A Closer Look</h2>
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions as of the end of 2023. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
<h3>MercadoLibre's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: MercadoLibre displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 41.94%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: MercadoLibre's net margin excels beyond industry benchmarks, reaching 3.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MercadoLibre's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.98%, the company showcases effective utilization of assets.
Debt Management: MercadoLibre's debt-to-equity ratio is below the industry average at 1.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MELI

Evaluating MercadoLibre: Insights From 10 Financial Analysts

Raymond James analyst Brad Sturges maintains AUTOMOTIVE PPTYS REAL EST INVT TR (TSX:<a class="ticker" href="https://www.benzinga.com/stock/APR#TSX">APR</a>) with a Outperform and lowers the price target from C$12.5 to C$12.

TSX:APR

Raymond James Maintains Outperform on AUTOMOTIVE PPTYS REAL EST INVT TR, Lowers Price Target to C$12

During the last three months, 4 analysts shared their evaluations of Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Nucor, presenting an average target of $206.25, a high estimate of $240.00, and a low estimate of $190.00. Surpassing the previous average price target of $191.25, the current average has increased by 7.84%.
<img src="https://www.benzinga.com/files/images/story/2024/1713978074_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Nucor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Alexander Hacking</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nucor. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nucor compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nucor's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NUE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nucor analyst ratings.</a>
<h2>About Nucor</h2>
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.
<h3>Financial Insights: Nucor</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Nucor faced challenges, resulting in a decline of approximately -11.69% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Nucor's net margin excels beyond industry benchmarks, reaching 9.97%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Nucor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.71%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Nucor's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.33.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 4 Analyst Evaluations For Nucor

During the last three months, 11 analysts shared their evaluations of Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.18, along with a high estimate of $50.00 and a low estimate of $37.00. This upward trend is apparent, with the current average reflecting a 11.66% increase from the previous average price target of $38.67.
<img src="https://www.benzinga.com/files/images/story/2024/1713978048_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Pinterest among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pinterest. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pinterest compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Pinterest's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pinterest's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PINS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pinterest analyst ratings.</a>
<h2>Unveiling the Story Behind Pinterest</h2>
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from cooking recipes to travel destinations. Founded in 2010, the platform consists of a largely female audience, which accounts for roughly two thirds of its nearly 500 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features. About 20% of users reside in the US and Canada, but the region accounted for about 80% of revenue in 2023.
<h3>Key Indicators: Pinterest's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Pinterest's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.86% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.
Net Margin: Pinterest's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.5%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.82%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Pinterest's ROA stands out, surpassing industry averages. With an impressive ROA of 5.83%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Pinterest adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PINS

What Analysts Are Saying About Pinterest Stock

Throughout the last three months, 11 analysts have evaluated HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.73, along with a high estimate of $38.00 and a low estimate of $25.00. Observing a 16.59% increase, the current average has risen from the previous average price target of $25.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1713978031_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of HashiCorp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Henderson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gray Powell</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Alex Henderson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HashiCorp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of HashiCorp compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of HashiCorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of HashiCorp's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HCP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on HashiCorp analyst ratings.</a>
<h2>About HashiCorp</h2>
HashiCorp Inc is engaged in solving the infrastructure challenges of cloud adoption by enabling an operating model that unlocks the full potential of modern public and private clouds. Its cloud operating model provides consistent workflows and a standardized approach to automate the processes involved in delivering applications in the cloud: infrastructure provisioning, security, networking, and application deployment. Its main commercial products are Terraform, Vault, Consul, and Nomad.
<h3>A Deep Dive into HashiCorp's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: HashiCorp's remarkable performance in 3 months is evident. As of 31 January, 2024, the company achieved an impressive revenue growth rate of 14.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: HashiCorp's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -20.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): HashiCorp's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.63%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): HashiCorp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.93%, the company may face hurdles in achieving optimal financial performance.
Debt Management: HashiCorp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For HashiCorp's Future

Trading Ideas

URNM

CNBC Halftime Report Final Trades: The Goldman Sachs Group, Meta Platforms, Sprott Uranium Miners ETF

B of A Securities analyst Tal Liani reiterates CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and maintains $315 price target.

Reiteration

CYBR

B of A Securities Reiterates Buy on CyberArk Software, Maintains $315 Price Target

Raymond James analyst Brian MacArthur maintains Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Outperform and raises the price target from $49.5 to $54.

Raymond James Maintains Outperform on Freeport-McMoRan, Raises Price Target to $54

HSBC analyst Ritchie Sun maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Buy and lowers the price target from $130 to $126.

NTES

HSBC Maintains Buy on NetEase, Lowers Price Target to $126

The boxing legend and marijuana entrepreneur behind cannabis brand Tyson 2.0, Mike Tyson, joined the marijuana seed bank Royal Queen Seeds (RQS) in taking over the famous One Times Square billboard in New York City celebrating 4/20. 
With a 20-story advertisement, Tyson, Royal Queen Seeds' president Shai Ramsahai and co-founder and CEO of CarmaHoldCo Adam Wilks marked New York's move toward legal and regulated home cultivation of cannabis for adults. 
"Growing cannabis at home is one of the most rewarding experiences, and for New Yorkers looking to cultivate, Royal Queen Seeds is a trusted partner throughout their journey, from seed germination to harvesting," stated Ramsahai. "Cannabis home grow should be legal, especially in the states where you can legally purchase cannabis as an adult for recreation, yet are still prohibited or outright criminalized for growing the same plant on your&nbsp;own&nbsp;private property."
The event took place following the <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> in Florida on April 16-17, where Tyson and his sidekick Ric Flair engaged in a competition over which one of them<a href="https://www.benzinga.com/markets/cannabis/24/04/38303764/exclusive-mike-tyson-or-ric-flair-who-can-smoke-more-weed" target="_blank" rel="noreferrer noopener"> can smoke the most weed.</a>
The 200-foot-tall One Times Square Billboard, famous for its New Year&#8217;s countdown, encouraged New Yorkers to grow their own cannabis and included a countdown to 4:20 p.m.
"Beyond the self-recorded benefits people enjoy from home cultivation, home growers develop a deeper understanding of and relationship with cannabis and mother nature," Ramsahai continued. "As one of the largest cannabis seed banks in the world, we will continue to advocate for fair and legal home cannabis cultivation laws and regulations for personal use."
Recently, Tyson 2.0 and&nbsp;Carma HoldCo Inc.&nbsp;announced their partnership with the multinational pharmaceutical company PHCANN to exclusively cultivate, manufacture&nbsp;and&nbsp;distribute TYSON 2.0 branded&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/04/38241174/exclusive-mike-tysons-cannabis-brand-tyson-2-0-partners-with-phcann-international-in-germany-uk-" rel="noreferrer noopener">THC products across Germany and the UK.</a>
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/03/37931455/new-yorkers-be-ready-to-bite-into-mike-tysons-new-cannabis-treats-heres-where-to-find-them" target="_blank" rel="noreferrer noopener">New Yorkers! Be Ready To Bite Into Mike Tyson&#8217;s New Cannabis Treats, Here&#8217;s Where To Find Them</a>
Courtesy photo&nbsp;

Mike Tyson Celebrates 4/20 With 200-Foot One Times Square Billboard Encouraging Home Cannabis Cultivation

HashiCorp Shares Resume Trading

FSD Pharma Inc (HUGE) is around the bottom of the Healthcare sector according to InvestorsObserver.HUGE received an overall rating of 21, which means that it scores higher than 21% of stocks. Additionally, FSD Pharma Inc scored a 8 in the Healthcare sector, ranking it higher than 8% of stocks in that sector. HUGE has an Ov

Should You Add FSD Pharma Inc (HUGE) Stock to Your Portfolio Wednesday?

Fsd Pharma (TSE:HUGE) has released an update. FSD Pharma, a biopharmaceutical company focusing on developing treatments for neurodegenerative and m...

FSD Pharma Reports Year-End Financials & R&D Progress

FSD Pharma GAAP EPS of -$0.46

FSD Pharma receives Nasdaq notification regarding minimum bid price deficiency

Fsd Pharma (TSE:HUGE) has released an update. FSD Pharma Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price...

FSD Pharma Faces Nasdaq Compliance Challenge

Fsd Pharma (TSE:HUGE) has released an update. FSD Pharma Inc. has been notified by Nasdaq of non-compliance with its minimum bid price rule but rem...

Fsd Pharma (TSE:HUGE) has released an update. FSD Pharma has bolstered its investment in Celly Nutrition Corp., a Canadian firm set to launch unbuz...

FSD Pharma Increases Stake in Recovery Drink Innovator

FSD Pharma expands pipeline investigation to include weight loss and liver health products

Fsd Pharma (TSE:HUGE) has released an update. FSD Pharma Inc., a biopharmaceutical company, announces the expansion of its research pipeline with a...

FSD Pharma Delves into Weight Loss and Liver Health

Fsd Pharma (TSE:HUGE) has released an update. FSD Pharma Inc. has announced that its affiliate, Celly Nutrition Corp., is gearing up to launch unbu...

FSD Pharma Gears Up for unbuzzd™ US Launch

Press Releases

FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)

FSD Pharma Announces Debt Settlement

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

FSD Pharma's Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here's Why

FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults

Earnings

FSD Pharma Announces Filing of Year-End 2023 Results

FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption